Is It Too Late to Buy Viking Therapeutics Stock?
Friday, 29 March 2024, 13:15
Why Viking's valuation may still go higher
For healthcare companies without revenue, much of the excitement depends on the pipeline's strength and trial results.
Last week, VK2735 showed promising effects with patients experiencing weight loss.
Optimism over clinical trials can drive the stock's value higher.
Why Viking Therapeutics' stock may struggle
If phase 3 trials do not prove efficacy and safety, the stock may face challenges.
Competition in the weight loss drug market and the company's high valuation could limit its upside potential.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.